Todays Report: Today: Ascendis Pharma A/S (ASND) Stock Rating Upgrade by The Zacks Investment Research

Today: Ascendis Pharma A/S (ASND) Stock Rating Upgrade by The Zacks Investment Research

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “

Several other research firms also recently weighed in on ASND. Wedbush started coverage on shares of Ascendis Pharma A/S in a report on Monday, September 26th. They issued an “outperform” rating and a $34.00 target price for the company. Leerink Swann reiterated a “buy” rating on shares of Ascendis Pharma A/S in a report on Friday, September 2nd. Finally, TheStreet upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Tuesday, September 6th.

Ascendis Pharma A/S (NASDAQ:ASND) traded down 0.61% during trading on Monday, hitting $20.51. The company had a trading volume of 58,181 shares. Ascendis Pharma A/S has a 52-week low of $11.92 and a 52-week high of $21.79. The firm’s 50 day moving average is $0.00 and its 200-day moving average is $0.00.

Several institutional investors have recently bought and sold shares of ASND. RA Capital Management LLC increased its position in Ascendis Pharma A/S by 7.9% in the third quarter. RA Capital Management LLC now owns 3,681,491 shares of the company’s stock valued at $73,998,000 after buying an additional 268,634 shares during the period. Baker BROS. Advisors LP acquired a new position in Ascendis Pharma A/S during the third quarter valued at approximately $14,985,000. Finally, Sphera Funds Management LTD. increased its position in Ascendis Pharma A/S by 0.6% in the third quarter. Sphera Funds Management LTD. now owns 263,500 shares of the company’s stock valued at $5,296,000 after buying an additional 1,700 shares during the period. Institutional investors and hedge funds own 44.40% of the company’s stock.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Related posts

Leave a Comment